Enlivex Therapeutics Ltd (ENLV)

Etorro trading 970x250
Enlivex Therapeutics Ltd (ENLV) Logo

About Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd operates as a clinical stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a universal, off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and various others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel. Address: 14 Einstein Street, Ness Ziona, Israel, 7403618

Enlivex Therapeutics Ltd News and around…

Latest news about Enlivex Therapeutics Ltd (ENLV) common stock and company :

Enlivex to Detail the Application of its Innovative Macrophage Reprogramming Cell Therapy to Unmet Needs in Oncology at the 11th Annual LifeSci Partners Corporate Access Event
03 Jan, 2022 Yahoo! Finance

** Management to participate in a panel discussion: “Innovative Approaches to Cell Therapy for Oncology,” which is taking place on Friday, January 7th, at 8:30 AM ET ** ** Panelists to discuss how their cell-based technologies, including, CAR-T cells, CAR-NK cells, TCR-T cells, and macrophage reprogramming, may address unmet needs in oncology ** Nes-Ziona, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming

Market Trend: Erratic And Unreliable
29 Dec, 2021 FinancialContent

Given the risks of covid variants and hefty price rises, the stock market should not be as buoyant as it is.

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
26 Dec, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

10 Micro-Cap Stocks to Buy According to Cathie Wood
14 Dec, 2021 Yahoo! Finance

In this article, we discuss the 10 micro-cap stocks to buy according to Cathie Wood. If you want to skip our detailed analysis of Cathie Wood’s investment philosophy and hedge fund performance, go directly to the 5 Micro-Cap Stocks to Buy According to Cathie Wood. Cathie Wood, the ARK Investment Management CEO, has been known […]

Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Greece
13 Dec, 2021 Yahoo! Finance

Nes-Ziona, Israel, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that, following a review of the Company’s preclinical and clinical data, study design, and manufacturing process, Greece’s National Organization of Medicines has authorized the expansion of the Company's Phase IIb trial evaluating AllocetraTM in severe and critical COVID-19 patients with acute respiratory di

Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece
07 Dec, 2021 Yahoo! Finance

Nes-Ziona, Israel, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that, following a review of the Company’s preclinical and clinical data, study design, and manufacturing process, Greece’s National Organization of Medicines has authorized the expansion of the Company’s Phase II trial of AllocetraTM in patients with pneumonia-associated sepsis to sites in the country. The p

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Treatment of Sepsis Patients with Allocetra
06 Dec, 2021 Yahoo! Finance

Nes-Ziona, Israel, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent application (number 16/194,417) covering AllocetraTM, the Company’s immunotherapy product candidate. Upon issuance, the patent will provide added intellectual property protection in the United States at least through 2036

Tuesday Markets Coverage
23 Nov, 2021 FinancialContent

GE was up on hopes for cheaper oil. But most stocks were down on oil price hike fears.

Enlivex Announces Third Quarter 2021 Financial Results and Provides a Business Update
22 Nov, 2021 Yahoo! Finance

Initiated dosing in placebo-controlled Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with ARDS Received authorization to expand ongoing sepsis and COVID-19 trials into Spain Initiated design and construction process for a new cGMP AllocetraTM manufacturing plant Nes Ziona, Israel, Nov. 22, 2021 (GLOBE NEWSWIRE) -- -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced

Wednesday Market Overview
10 Nov, 2021 FinancialContent

Inflation came in at 6.2% in October which boosted gold and of course the new hedge, bitcoin

Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain
10 Nov, 2021 Yahoo! Finance

Nes Ziona, Israel, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has authorized the expansion of the Company’s Phase IIb trial evaluating AllocetraTM in severe and critical COVID-19 patients with acute respiratory distress syndrome (ARDS) to sites in Spain. The placebo-controlled trial, which is currently en

Spanish Regulator Grants Enlivex Authorization To Expand Its Sepsis Phase II into Spain
04 Nov, 2021 Yahoo! Finance

Nes Ziona, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has authorized the expansion to clinical sites in Spain of the Company's multi-center, placebo-controlled, randomized, dose-finding, Phase II trial of AllocetraTM in patients with pneumonia-associated sepsis. The Phase II trial, which has multi

Election Day
03 Nov, 2021 FinancialContent

Teva rose a whopping 8.34% today.

Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine
12 Oct, 2021 Yahoo! Finance

Publication follows the Israeli Ministry of Health’s appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19 vaccines Nes-Ziona, Israel, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that its Chief Scientific Officer, Prof. Dror Mevorach, M.D., and several co-authors published a foundational peer reviewed paper in The New Engla

Enlivex Receives Notice of Allowance for Israeli Patent Application Covering Allocetra Derived from Pooled Donor Cells
05 Oct, 2021 Yahoo! Finance

Nes-Ziona, Israel, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that the Israeli Patent Office issued a notice of allowance for a new patent application (number 255119) covering AllocetraTM, the Company’s immunotherapy product candidate. Upon issuance, the patent will provide added intellec

Enlivex Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data from Phase Ib Trial Evaluating Allocetra in Patients with Sepsis
04 Oct, 2021 Yahoo! Finance

Data published in Frontiers in Immunology show a robust safety profile and substantial improvements in state of organ failure, duration of ICU stay, and mortality in 10 Allocetra-treated severe sepsis patients vs. matched historical controlsNes-Ziona, Israel, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the peer-reviewed publication of clinical data from the Company’s Ph

A Bit Of A Recovery
29 Sep, 2021 FinancialContent

While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week.

Enlivex to Present at Reuters Events' Cell & Gene Therapy USA 2021
29 Sep, 2021 FinancialContent
Enlivex Therapeutics (ENLV) Sees Hammer Chart Pattern: Time to Buy?
27 Sep, 2021 Yahoo! Finance

Enlivex Therapeutics (ENLV) has been struggling lately, but the selling pressure may be coming to an end soon.

China's Rescue Of Evergrand
23 Sep, 2021 FinancialContent

The number of jobless last week was higher than the forecast, at 351,000 vs 320,000. The recovery is lagging. 

Enlivex (ENLV) Begins Phase IIb COVID-19 Study on Cell Therapy
23 Sep, 2021 Yahoo! Finance

Enlivex (ENLV) doses the first patient in a phase IIb study evaluating its cell therapy, Allocetra, in severe and critical COVID-19 patients with acute respiratory distress syndrome.

Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS
22 Sep, 2021 FinancialContent
Enlivex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
09 Sep, 2021 FinancialContent
Here's Why Enlivex Therapeutics Ltd. (ENLV) is a Great Momentum Stock to Buy
03 Sep, 2021 Yahoo! Finance

Does Enlivex Therapeutics Ltd. (ENLV) have what it takes to be a top stock pick for momentum investors? Let's find out.

54 Biggest Movers From Yesterday
02 Sep, 2021 FinancialContent

Gainers Focus Universal Inc. (NASDAQ: FCUV) shares climbed 278% to close at $19.28 on Wednesday. The stock started trading on ...

55 Biggest Movers From Yesterday
01 Sep, 2021 FinancialContent

Gainers Unico American Corporation (NASDAQ: UNAM) shares gained 59% to close at $4.15 on Tuesday. Elys Game Technology, Corp. ...

Vaccine Victory Lap
24 Aug, 2021 FinancialContent

Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson Hole Symposium kicks off remains to be seen.

Now That The FDA Approved Pfizer-BioNTech, Is This It For Vaccine Stocks?
23 Aug, 2021 FinancialContent

If there's one thing to take away from any conversation about biotech stocks, it's that any company with their hat in the ring is likely making a version of something they hope to be better than the currently available method.

60 Biggest Movers From Yesterday
17 Aug, 2021 FinancialContent

Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to ...

Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet
16 Aug, 2021 FinancialContent

Toward the end of trading Monday, the Dow traded up 0.03% to 35,526.99 while the NASDAQ fell 0.34% to 14,771.91. The S&P also rose, ...

Enlivex Therapeutics Ltd (ENLV) is a NASDAQ Common Stock listed in , ,

970x250